RU2010117397A - COMPOUNDS AND COMPOSITIONS INHIBITING PARP AND WAYS OF THEIR APPLICATION - Google Patents
COMPOUNDS AND COMPOSITIONS INHIBITING PARP AND WAYS OF THEIR APPLICATION Download PDFInfo
- Publication number
- RU2010117397A RU2010117397A RU2010117397/13A RU2010117397A RU2010117397A RU 2010117397 A RU2010117397 A RU 2010117397A RU 2010117397/13 A RU2010117397/13 A RU 2010117397/13A RU 2010117397 A RU2010117397 A RU 2010117397A RU 2010117397 A RU2010117397 A RU 2010117397A
- Authority
- RU
- Russia
- Prior art keywords
- straight
- branched chain
- alkyl
- cancer
- alkenyl
- Prior art date
Links
- 0 *CC(N1)=Nc(cccc23)c2C1=NNC3=O Chemical compound *CC(N1)=Nc(cccc23)c2C1=NNC3=O 0.000 description 1
- RRILJSQCJPYCBE-UHFFFAOYSA-N CN(CCN(CC(N1)=Nc(cccc23)c2C1=NNC3=O)CC1)C1c(ccc(N=C(CN(CC1)CCC1c1c[nH]c2c1cccc2)N1)c2C1=NN1)c2C1=O Chemical compound CN(CCN(CC(N1)=Nc(cccc23)c2C1=NNC3=O)CC1)C1c(ccc(N=C(CN(CC1)CCC1c1c[nH]c2c1cccc2)N1)c2C1=NN1)c2C1=O RRILJSQCJPYCBE-UHFFFAOYSA-N 0.000 description 1
- JLFSBHQQXIAQEC-UHFFFAOYSA-N O=C1NN=C2NC(CN(C3)Cc4c3cccc4)=Nc3c2c1ccc3 Chemical compound O=C1NN=C2NC(CN(C3)Cc4c3cccc4)=Nc3c2c1ccc3 JLFSBHQQXIAQEC-UHFFFAOYSA-N 0.000 description 1
- WCQTUVHOMVMRFB-UHFFFAOYSA-N O=C1NN=C2NC(CN(CCC3)CCN3S(c3ccccc3)(=O)=O)=Nc3c2c1ccc3 Chemical compound O=C1NN=C2NC(CN(CCC3)CCN3S(c3ccccc3)(=O)=O)=Nc3c2c1ccc3 WCQTUVHOMVMRFB-UHFFFAOYSA-N 0.000 description 1
- YQPHVGZWALUTJX-UHFFFAOYSA-N O=C1NN=C2NC(CNCCc3cc(F)ccc3)=Nc3c2c1ccc3 Chemical compound O=C1NN=C2NC(CNCCc3cc(F)ccc3)=Nc3c2c1ccc3 YQPHVGZWALUTJX-UHFFFAOYSA-N 0.000 description 1
- YEYMMWGQIVDEJH-UHFFFAOYSA-N O=C1NN=C2NC(CNCc3cc(C(F)(F)F)ccc3)=Nc3c2c1ccc3 Chemical compound O=C1NN=C2NC(CNCc3cc(C(F)(F)F)ccc3)=Nc3c2c1ccc3 YEYMMWGQIVDEJH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1. Соединение формулы (I) или его фармацевтически приемлемая соль: ! ! где R означает ! (a) NR1R2, где R1 выбирают из группы, включающей водород, C1-C6алкил с линейной или разветвленной цепью, C2-C6алкенил с линейной или разветвленной цепью, C3-C8циклоалкил, C1-C6алкокси, C2-C6алкенилокси, фенил, фенокси, бензилокси, NRARB(C1-C6алкил с линейной или разветвленной цепью), NRARB(C2-C6алкенил с линейной или разветвленной цепью), (C1-C6алкил с линейной или разветвленной цепью)карбонил, (C2-C6алкенил с линейной или разветвленной цепью)карбонил, (C3-C8циклоалкил)карбонил, (C1-C6алкил с линейной или разветвленной цепью)оксикарбонил, (C2-C6алкенил с линейной или разветвленной цепью)оксикарбонил, (C3-C8циклоалкил)оксикарбонил, арилкарбонил, сульфонил, арилсульфонил, арил(C1-C6алкил с линейной или разветвленной цепью), арил(C2-C6алкенил с линейной или разветвленной цепью), арил(C3-C8циклоалкил), (C1-C6алкил с линейной или разветвленной цепью)арил, (C2-C6алкенил с линейной или разветвленной цепью)арил, (C3-C8циклоалкил)арил, арил, гетероциклил, гетероциклил(C1-C6алкил с линейной или разветвленной цепью) и гетероциклил(C2-C6алкенил с линейной или разветвленной цепью); где каждый гетероциклил содержит от 1 до 7 гетероатомов, независимо выбранных из O, N или S, и где каждый из RA и RB независимо выбирают из группы, включающей водород, C1-C6алкил с линейной или разветвленной цепью, C2-C6алкенил с линейной или разветвленной цепью и C3-C8циклоалкил; ! и R2 выбирают из группы, включающей C1-C6алкил с линейной или разветвленной цепью, C2-C6алкенил с линейной или разветвленной цепью, C3-C8циклоалкил, C1-C6алкокси, C2-C6алкенилокси, фенил, фенокси, бензилокси, NRXRY(C1-C6алкил с линейной или разветвленной цепью), NRXRY(C2-C6алкенил � 1. The compound of formula (I) or its pharmaceutically acceptable salt:! ! where R means! (a) NR1R2, where R1 is selected from the group consisting of hydrogen, straight or branched chain C1-C6 alkyl, straight or branched chain C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C2-C6 alkenyloxy, phenyl, phenoxy, benzyloxy, NRARB (C1-C6 straight or branched chain alkyl), NRARB (C2-C6 straight or branched chain), (C1-C6 straight or branched chain) carbonyl, (C2-C6 straight or branched chain) carbonyl, (C3 -C8 cycloalkyl) carbonyl, (C1-C6 straight or branched chain alkyl) hydroxycarbonyl, (C2-C6 alkenyl straight or branched chain) hydroxycarbonyl, (C3-C8 cycloalkyl) hydroxycarbonyl, arylcarbonyl, sulfonyl, arylsulfonyl, aryl (C1-C6 straight or branched chain), aryl (C2-C6 straight or branched chain), aryl (C3-C8 cyclo Branched C1-C6 alkyl) aryl, (C2-C6 straight or branched chain C2-alkenyl) aryl, (C3-C8 cycloalkyl) aryl, aryl, heterocyclyl, heterocyclyl (straight or branched chain C1-C6) and heterocyclyl (C2 Straight chain or branched C6 alkenyl); where each heterocyclyl contains from 1 to 7 heteroatoms independently selected from O, N or S, and where each of RA and RB is independently selected from the group consisting of hydrogen, straight or branched chain C1-C6 alkyl, straight or branched C2-C6 alkenyl chain and C3-C8 cycloalkyl; ! and R2 are selected from the group consisting of straight or branched chain C1-C6 alkyl, straight or branched chain C2-C6 alkenyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C2-C6 alkenyloxy, phenyl, phenoxy, benzyloxy, NRXRY (C1-C6 alkyl or branched chain), NRXRY (C2-C6 alkenyl �
Claims (49)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97711507P | 2007-10-03 | 2007-10-03 | |
US60/977,115 | 2007-10-03 | ||
PCT/US2008/078606 WO2009046205A1 (en) | 2007-10-03 | 2008-10-02 | Parp inhibitor compounds, compositions and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010117397A true RU2010117397A (en) | 2011-11-10 |
RU2485122C2 RU2485122C2 (en) | 2013-06-20 |
Family
ID=40526672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010117397/04A RU2485122C2 (en) | 2007-10-03 | 2008-10-02 | Parp-inhibiting compounds and compositions, and methods for using them |
Country Status (28)
Country | Link |
---|---|
US (3) | US8236802B2 (en) |
EP (2) | EP2842956A1 (en) |
JP (1) | JP5439380B2 (en) |
KR (1) | KR101596526B1 (en) |
CN (1) | CN102083314B (en) |
AU (1) | AU2008308664B2 (en) |
BR (1) | BRPI0820518B1 (en) |
CA (1) | CA2700903C (en) |
CL (1) | CL2010000320A1 (en) |
CY (1) | CY1115747T1 (en) |
DK (1) | DK2209375T3 (en) |
ES (1) | ES2504690T3 (en) |
HK (1) | HK1146792A1 (en) |
HR (1) | HRP20140853T1 (en) |
IL (1) | IL204776A (en) |
JO (1) | JO3170B1 (en) |
MX (1) | MX2010003564A (en) |
MY (1) | MY155237A (en) |
NZ (1) | NZ585012A (en) |
PL (1) | PL2209375T3 (en) |
PT (1) | PT2209375E (en) |
RU (1) | RU2485122C2 (en) |
SG (1) | SG185272A1 (en) |
SI (1) | SI2209375T1 (en) |
TW (1) | TWI426912B (en) |
UA (1) | UA99483C2 (en) |
WO (1) | WO2009046205A1 (en) |
ZA (1) | ZA201002317B (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007008771A (en) | 2005-01-19 | 2007-09-11 | Mgi Gp Inc | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp. |
JP5439380B2 (en) | 2007-10-03 | 2014-03-12 | エーザイ インク. | PARP inhibiting compounds, compositions and methods of use |
ES2625817T3 (en) * | 2008-08-06 | 2017-07-20 | Medivation Technologies, Inc. | Dihydropyridophthalazinone-type poly (ADP-ribose) polymerase (PARP) inhibitors |
EP2322658A1 (en) | 2009-11-13 | 2011-05-18 | Centre National de la Recherche Scientifique (CNRS) | Signature for the diagnosis of breast cancer aggressiveness and genetic instability |
KR101826652B1 (en) * | 2010-02-08 | 2018-02-07 | 메디베이션 테크놀로지즈, 인크. | Processes of synthesizing dihydropyridophthalazinone derivatives |
DK3012329T3 (en) | 2010-06-18 | 2017-11-20 | Myriad Genetics Inc | METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY |
US9649394B2 (en) | 2010-11-22 | 2017-05-16 | The General Hospital Corporation | Compositions and methods for in vivo imaging |
EP2683825B1 (en) * | 2011-03-11 | 2017-01-04 | Sarissa Inc. | Methods of treating cancer by inhibition of dna repair proteins |
TW201244714A (en) * | 2011-04-11 | 2012-11-16 | Abbott Lab | PARP inhibitors for the treatment of CIPN |
WO2012156501A1 (en) | 2011-05-18 | 2012-11-22 | Centre National De La Recherche Scientifique (Cnrs) | Signature for the diagnosis of cancer aggressiveness and genetic instability |
CN103781776A (en) * | 2011-07-13 | 2014-05-07 | 诺华股份有限公司 | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
WO2013028495A1 (en) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
AU2012358244A1 (en) * | 2011-12-21 | 2014-06-12 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
US9790556B2 (en) | 2012-01-05 | 2017-10-17 | Centre National De La Recherche Scientifique (Cnrs) | Signature for the diagnosis of lung cancer aggressiveness and genetic instability |
JP2016519684A (en) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | Methods and compositions for improving the efficacy of suboptimally administered medication and / or reducing side effects |
CN112472699A (en) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | Combination methods for improving the therapeutic benefit of bisantrene and derivatives |
CN106659765B (en) | 2014-04-04 | 2021-08-13 | 德玛医药 | Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer |
JP6648040B2 (en) * | 2014-05-28 | 2020-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Use of eribulin and poly (ADP-ribose) polymerase (PARP) inhibitors as combination therapy for cancer treatment |
TW201702218A (en) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
US11261466B2 (en) | 2015-03-02 | 2022-03-01 | Sinai Health System | Homologous recombination factors |
CN104945406B (en) * | 2015-05-25 | 2017-10-10 | 苏州康润医药有限公司 | Derivative, its preparation method and its application as PARP inhibitor of that non-ketone of alkene 3 of azepine |
CN108138177B9 (en) | 2015-07-23 | 2021-08-13 | 法国居里学院 | Use of Dbait molecules in combination with PARP inhibitors for the treatment of cancer |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
US20200230134A1 (en) * | 2017-03-09 | 2020-07-23 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
KR20220079938A (en) * | 2019-10-10 | 2022-06-14 | 에스테베 파마슈티칼스 에스에이 | Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives with multimodal activity against pain |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021249996A1 (en) | 2020-06-08 | 2021-12-16 | Oncology Venture ApS | Compositions comprising 2x-121 and methods for treating coronavirus infection |
CN114053276B (en) * | 2020-07-30 | 2024-05-07 | 江苏天士力帝益药业有限公司 | Application of PARP inhibitor TSL-1502 intermediate TSL-1502M |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
US6291425B1 (en) * | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
AU9298098A (en) | 1997-09-03 | 1999-03-22 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
US5950784A (en) | 1997-09-03 | 1999-09-14 | Yang; Shu-Chiung C. | Hub structural improvement |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
CA2332279A1 (en) | 1998-05-15 | 1999-11-25 | Jia-He Li | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
US6201020B1 (en) | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
US6387902B1 (en) | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
SI20691B (en) | 1999-01-11 | 2008-10-31 | Agouron Pharma | Tricyclic inhibitors of poly(adp-ribose) polymerases |
WO2001057038A1 (en) | 2000-02-01 | 2001-08-09 | Basf Aktiengesellschaft | Heterocyclic compounds and their use as parp inhibitors |
US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
DE10022925A1 (en) | 2000-05-11 | 2001-11-15 | Basf Ag | New indole-carboxamide or azepino-indole derivatives and analogs, are poly-ADP ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, ischemia, epilepsy, tumors, sepsis or diabetes mellitus |
CA2517629C (en) * | 2003-03-12 | 2011-07-12 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7268138B2 (en) | 2003-05-28 | 2007-09-11 | Mgi Gp, Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
MXPA05013145A (en) * | 2003-06-10 | 2006-03-17 | Hoffmann La Roche | 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives. |
KR101138471B1 (en) | 2003-07-25 | 2012-04-25 | 화이자 인코포레이티드 | Tricyclic parp inhibitors |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
CN102107008B (en) | 2003-12-01 | 2013-04-03 | 库多斯药物有限公司 | DNA damage repair inhibitors for treatment of cancer |
JP4964772B2 (en) | 2004-08-04 | 2012-07-04 | フォスフォニックス リミテッド | Substituted organopolysiloxanes and their use |
MX2007008771A (en) * | 2005-01-19 | 2007-09-11 | Mgi Gp Inc | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp. |
JP5439380B2 (en) | 2007-10-03 | 2014-03-12 | エーザイ インク. | PARP inhibiting compounds, compositions and methods of use |
WO2009137411A1 (en) | 2008-05-09 | 2009-11-12 | Allergan, Inc. | Therapeutic compounds |
CN103097355A (en) | 2010-07-08 | 2013-05-08 | 惠氏有限责任公司 | Novel quinoline esters useful for treating skin disorders |
-
2008
- 2008-10-02 JP JP2010528132A patent/JP5439380B2/en active Active
- 2008-10-02 UA UAA201005117A patent/UA99483C2/en unknown
- 2008-10-02 EP EP14179976.7A patent/EP2842956A1/en not_active Withdrawn
- 2008-10-02 SG SG2012073482A patent/SG185272A1/en unknown
- 2008-10-02 AU AU2008308664A patent/AU2008308664B2/en active Active
- 2008-10-02 DK DK08836018.5T patent/DK2209375T3/en active
- 2008-10-02 MY MYPI2010001496A patent/MY155237A/en unknown
- 2008-10-02 NZ NZ585012A patent/NZ585012A/en unknown
- 2008-10-02 CN CN200880118681.4A patent/CN102083314B/en active Active
- 2008-10-02 PL PL08836018T patent/PL2209375T3/en unknown
- 2008-10-02 ES ES08836018.5T patent/ES2504690T3/en active Active
- 2008-10-02 BR BRPI0820518-3A patent/BRPI0820518B1/en active IP Right Grant
- 2008-10-02 US US12/244,399 patent/US8236802B2/en active Active
- 2008-10-02 EP EP08836018.5A patent/EP2209375B1/en active Active
- 2008-10-02 WO PCT/US2008/078606 patent/WO2009046205A1/en active Application Filing
- 2008-10-02 PT PT88360185T patent/PT2209375E/en unknown
- 2008-10-02 MX MX2010003564A patent/MX2010003564A/en active IP Right Grant
- 2008-10-02 CA CA2700903A patent/CA2700903C/en active Active
- 2008-10-02 KR KR1020107009588A patent/KR101596526B1/en active IP Right Grant
- 2008-10-02 RU RU2010117397/04A patent/RU2485122C2/en active
- 2008-10-02 SI SI200831302T patent/SI2209375T1/en unknown
- 2008-10-03 TW TW097138166A patent/TWI426912B/en active
- 2008-10-05 JO JOP/2008/0433A patent/JO3170B1/en active
-
2010
- 2010-03-28 IL IL204776A patent/IL204776A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02317A patent/ZA201002317B/en unknown
- 2010-04-05 CL CL2010000320A patent/CL2010000320A1/en unknown
-
2011
- 2011-01-28 HK HK11100918.6A patent/HK1146792A1/en unknown
-
2012
- 2012-06-19 US US13/527,158 patent/US8894989B2/en active Active
-
2014
- 2014-09-09 HR HRP20140853AT patent/HRP20140853T1/en unknown
- 2014-09-25 CY CY20141100783T patent/CY1115747T1/en unknown
- 2014-11-11 US US14/538,447 patent/US20150141429A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010117397A (en) | COMPOUNDS AND COMPOSITIONS INHIBITING PARP AND WAYS OF THEIR APPLICATION | |
JP2010540655A5 (en) | ||
JP6612892B2 (en) | Nitrobenzyl derivatives of anticancer agents | |
JP5685231B2 (en) | Diazabenzo [de] anthracen-3-one compound and method for inhibiting PARP | |
RU2006131591A (en) | METHOD FOR PRODUCING 2-AMINOTIAZOL-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | |
WO2018075994A1 (en) | Compounds and methods to sensitize cancer cells to cisplatin | |
IL289165B1 (en) | Substituted azole-dione compounds and pharmaceutical compositions comprising them | |
RU2016130986A (en) | KINASE INHIBITOR AND ITS APPLICATION | |
CN103327977B (en) | Dyscrasic treatment or prophylactic | |
KR101230085B1 (en) | Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo[1,2-a]pyridine-3-yl-2,5-dioxo-1h-pyrrol-3-yl)-9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinyl-carbonyl)-pyrrolo[3,2,1-jk][1,4]benzodiazepine | |
KR20070086595A (en) | Tubulin binding anticancer agents and prodrugs thereof | |
BRPI0408876A (en) | indazole derivative, pharmaceutical composition, anti-tumor and therapeutic agents, use of the indazole derivative or pharmaceutically acceptable salt thereof, and methods for treating tumor, treating leukemia, treating myeloma or lymphoma, treating carcinoma solid and to treat cancer | |
HRP20100561T1 (en) | Inhibitors of the interaction between mdm2 and p53 | |
EP2979700B1 (en) | Antitumor agent including low dose irinotecan hydrochloride hydrate | |
CA2389545A1 (en) | Chemokine receptor binding heterocyclic compounds | |
JP2011506402A5 (en) | ||
RU2003137007A (en) | NEW Pyridylcyanoguanidine Compounds | |
EA016838B1 (en) | Methods of treating cancer and other conditions or disease states using clevudine (lfmau) and telbivudine (ldt) | |
Kelson et al. | 1, 2, 4-Benzotriazine 1, 4-dioxides. An important class of hypoxic cytotoxins with antitumor activity | |
CN111836628A (en) | Antitumor agent, antitumor effect enhancer, and antitumor kit | |
CN105307682A (en) | Antitumor agent | |
CA2594508A1 (en) | Cyanoguanidine compounds | |
CA2600712A1 (en) | Methods of treating cancer using ppar-gamma antagonists | |
Gond et al. | Isolation of potassium salt of oxadiazole-2-thione and in vitro anticancer activities of its Cu (ii) and Zn (ii) complexes against MDA-MB-231 human breast carcinoma cells | |
JPWO2021007307A5 (en) |